Myriad Genetics (MYGN) Stock Price
Myriad Genetics Price
Revenue has compounded at 11.0% per year over the past 19 years to 824.50 M USD. Earnings per share have declined at 17.1% per year over the last 11 years. Myriad Genetics's net margin stands at -44.4%, down from -3.9% several years earlier. Analysts set a median price target of 3.00 USD, implying 29.9% below the current price. Of 15 analysts, 2 rate the stock a buy — an overall Hold consensus.
Myriad Genetics stock price
Myriad Genetics business model & stock analysis
Frequently asked questions about Myriad Genetics
The business model of Myriad Genetics Inc revolves around providing molecular diagnostic tests and genetic analysis services. As a leading molecular diagnostics company, Myriad Genetics focuses on developing and marketing innovative genetic tests for various medical conditions, including cancer and genetic disorders. With a strong emphasis on research and technology, Myriad Genetics aims to improve patient care and outcomes through personalized medicine. By offering a wide range of genetic testing services, the company strives to empower healthcare providers and individuals with valuable genetic insights, enabling more precise diagnosis, treatment decisions, and proactive healthcare management. Myriad Genetics Inc's business model primarily centers on genetic testing for various medical conditions.
Myriad Genetics Inc is primarily active in the healthcare and biotechnology industries.
The main competitors of Myriad Genetics Inc in the market include companies like Invitae Corporation, Illumina Inc, NeoGenomics Laboratories Inc, and Natera Inc.
Myriad Genetics Inc is a leading molecular diagnostics company based in the United States. Founded in 1991, the company has a rich history and has made significant contributions to the field of genetic testing and personalized medicine. Myriad Genetics Inc specializes in developing and marketing innovative genetic tests, including those for hereditary cancer and rare diseases. With a strong focus on research and development, the company has established itself as a trusted provider of genetic testing services worldwide. Myriad Genetics Inc's commitment to advancing healthcare through genetic insights has made it a prominent player in the industry.
Myriad Genetics Inc has achieved several significant milestones throughout its history. One notable achievement is the development of the BRACAnalysis test, which is a groundbreaking genetic test used to identify individuals with a higher risk of developing hereditary breast and ovarian cancer. This test has revolutionized the field of genetic testing and has had a major impact on cancer prevention and treatment. Additionally, Myriad Genetics Inc has successfully expanded its portfolio to include various genetic tests for other diseases, including prostate cancer and hereditary colon cancer. The company continues to innovate and make strides in the field of genetic testing, solidifying its position as a leader in the industry.
Myriad Genetics Inc is primarily present in various countries and regions worldwide. The company has a global presence, with operations and offices in several key locations. Some of the countries and regions where Myriad Genetics Inc is primarily present include the United States, Canada, Europe (including countries like the United Kingdom, France, Germany, Italy, and Spain), Asia Pacific (including countries like Japan, China, and Australia), and Latin America. This widespread presence allows Myriad Genetics Inc to serve a wide range of customers and collaborate with medical professionals and researchers globally.
Myriad Genetics Inc represents values of innovation, dedication to patients, and commitment to improving healthcare through genetic testing and personalized medicine. With a corporate philosophy centered around advancing precision medicine, Myriad Genetics is focused on developing groundbreaking molecular diagnostic tests that enable early detection and prevention of diseases such as cancer. The company aims to empower healthcare professionals and patients with reliable, actionable genetic information to make informed decisions about treatment and preventative measures. Myriad Genetics' dedication to quality, accuracy, and ethical practices makes it a trusted leader in the field of genetic testing and precision medicine.
Analysts currently set an average price target of 4.00 USD for the Myriad Genetics stock (median: 3.00 USD), implying -6.5 % versus the latest price. The consensus is based on 15 analyst ratings.
15 analysts currently rate the Myriad Genetics stock: 2 recommend buying, 8 holding and 5 selling. For 2026, analysts expect Myriad Genetics to generate revenue of 777.92 M USD and earnings per share of -0.71 USD.
Converted at the current exchange rate, the Myriad Genetics share trades at 3.82 EUR (4.28 USD).
The Myriad Genetics share (MYGN) is listed on 9 stock exchanges, including: NASDAQ (MYGN), London (0K3W.L), SIX (Zürich) (MYD.SW), XETRA (MYD.DE), Frankfurt (MYD.F), München (MYD.MU), Düsseldorf (MYD.DU), Hamburg (MYD.HM).
The company Myriad Genetics Inc. is a US-American company that specializes in the development and marketing of medical testing procedures and personalized medicine solutions. The business model includes three main divisions: genetic testing, molecular diagnostics, and personalized medicine. In the genetic testing division, Myriad Genetics offers a comprehensive range of genetic tests, including BRCA1 and BRCA2 tests, which are specifically designed to identify the risk of breast cancer in women and men. In addition, the company offers tests for hereditary colon and skin cancer, as well as tests for genetic disorders and hereditary types of cancer. These tests are aimed at providing doctors with a solid basis for making informed decisions, diagnosing accurately, and choosing the best treatment options for their patients. In molecular diagnostics, the company focuses on developing testing procedures specifically designed to identify the genetic basis of certain diseases. Myriad Genetics has developed a wide range of molecular tests that are used in the early detection and treatment of diseases such as breast cancer, colon cancer, and prostate cancer. Personalized medicine reflects the core idea of Myriad Genetics' business model. It involves using a patient's genetics to develop individualized treatment options. The company has developed various technologies tailored to an individual's genetic profile to enable better prediction of the effectiveness of medications and therapies. The goal is to create tailored, targeted treatment methods for patients through personalized medicine and genomic therapies. An important part of Myriad Genetics' business is collaboration with leading researchers, doctors, and medical institutions worldwide. The company has established partnerships with leading oncologists and cancer centers to promote the use of tests and personalized medicine solutions. Additionally, Myriad Genetics has a strong research department that continuously focuses on new technologies and innovative therapies for the treatment of cancer and other serious illnesses. Overall, Myriad Genetics' business model offers a comprehensive range of innovative products and services for the medical community and patients worldwide. The company continuously works to expand and improve its offerings in order to provide the best possible diagnosis and treatment options based on the individual genetic characteristics of each patient.
The expected revenue of Myriad Genetics is 777.92 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Myriad Genetics is -66.69 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Myriad Genetics is currently -5.99. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Myriad Genetics stock.
The price-to-sales ratio (P/S) of Myriad Genetics is currently 0.51. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Myriad Genetics stock.
The Eulerpool Quality Score for Myriad Genetics is 2/10.
The ISIN of Myriad Genetics is US62855J1043. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Myriad Genetics is 897518. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Myriad Genetics is MYGN. The ticker symbol is used to trade Myriad Genetics shares on the stock exchange.
Myriad Genetics stock
Myriad Genetics Peer Group
Myriad Genetics Ticker
Myriad Genetics FIGI
All fundamentals and in-depth analysis of Myriad Genetics
Our stock analysis for Myriad Genetics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Myriad Genetics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.